BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7920000)

  • 1. Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry.
    Wakasugi M; Wakao R; Tawata M; Gan N; Inoue M; Koizumi K; Onaya T
    Thyroid; 1994; 4(2):179-82. PubMed ID: 7920000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves' disease.
    Amashukeli M; Korinteli M; Zerekidze T; Jikurauli N; Shanava S; Tsagareli M; Giorgadze E
    J Investig Med; 2013 Jun; 61(5):842-7. PubMed ID: 23612147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.
    Lucidarme N; Ruiz JC; Czernichow P; Léger J
    J Pediatr; 2000 Jul; 137(1):56-62. PubMed ID: 10891822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry.
    Wakasugi M; Wakao R; Tawata M; Gan N; Koizumi K; Onaya T
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):283-6. PubMed ID: 8096166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Graves' disease during puberty influence adult bone mineral density?
    Radetti G; Bona G; Corrias A; Cappa M; DeSanctis V; Lauriola S; Paganini C; Rigon F
    Horm Res; 2002; 58(4):176-9. PubMed ID: 12324715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.
    Jódar E; Muñoz-Torres M; Escobar-Jiménez F; Quesada-Charneco M; Lund del Castillo JD
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):279-85. PubMed ID: 9373448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism.
    Lee MS; Kim SY; Lee MC; Cho BY; Lee HK; Koh CS; Min HK
    J Clin Endocrinol Metab; 1990 Mar; 70(3):766-70. PubMed ID: 2307730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
    Siderova M; Hristozov K; Tsukeva A
    Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density after surgical treatment for Graves' disease.
    Arata N; Momotani N; Maruyama H; Saruta T; Tsukatani K; Kubo A; Ikemoto K; Ito K
    Thyroid; 1997 Aug; 7(4):547-54. PubMed ID: 9292941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The characteristics of osteoporotic patients in Graves' disease patients newly diagnosed after menopause: a prospective observational study.
    Yoshihara A; Yoshimura Noh J; Mukasa K; Watanabe N; Iwaku K; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Suzuki N; Endo K; Suzuki R; Hattori N; Sugino K; Ito K
    Endocr J; 2016 Dec; 63(12):1113-1122. PubMed ID: 27600197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
    Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotoxic bone disease in women: a potentially reversible disorder.
    Diamond T; Vine J; Smart R; Butler P
    Ann Intern Med; 1994 Jan; 120(1):8-11. PubMed ID: 8250460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.